HRT
HRT and Breast Cancer Risk — What the UK Evidence Says
The real numbers behind HRT and breast cancer risk, put in plain-English context for UK women.
Modern body-identical HRT carries a small, dose-dependent risk that most women weigh against significant symptom, bone and cardiovascular benefits. This guide translates the CGHFBC and MHRA data into practical decisions.
The breast cancer conversation dominates HRT decisions — often more than it should. Twenty years of alarmist headlines from the 2002 Women’s Health Initiative (WHI) study have left a legacy of fear that modern data no longer supports. The truth is more nuanced and much less frightening: any breast cancer risk from HRT is small, dose- and duration-dependent, largely dependent on which progestogen you use, and needs to be weighed against real, quantifiable benefits for bones, heart, brain, urogenital health and quality of life. Understanding the numbers — rather than the headlines — makes this decision genuinely informed.
What the modern evidence actually shows
- Oestrogen-only HRT (used after hysterectomy): no meaningful increase in breast cancer incidence, and the WHI oestrogen-only arm actually showed a small reduction in breast cancer mortality over 20-year follow-up.
- Combined HRT with body-identical micronised progesterone (Utrogestan): no clear increase in breast cancer risk in the first 5 years of use, based on the French E3N cohort.
- Combined HRT with older synthetic progestogens (norethisterone, MPA, dydrogesterone): a small absolute increase — around 1 extra case per 1,000 women per year of use after 5 years.
- Any small increase reduces once HRT is stopped and returns to baseline within a few years.
- The WHI participants had an average age of 63 and higher baseline risk factors than the typical UK menopause patient — their results do not transfer directly to a 51-year-old starting HRT for symptoms.
Absolute risk in numbers, not percentages
- The lifetime breast cancer risk for a UK woman is around 1 in 7 (roughly 143 per 1,000).
- 5 years of combined HRT with an older synthetic progestogen adds around 5 extra cases per 1,000 users beyond baseline.
- 5 years of combined HRT with micronised progesterone: no clear extra cases in trial data.
- 5 years of oestrogen-only HRT: possibly fewer cases than baseline.
- Being overweight (BMI 30+) adds around 24 extra cases per 1,000 women over the same period.
- Drinking 2+ units of alcohol daily adds around 5 extra cases per 1,000.
- Perspective matters: modifiable lifestyle factors typically outweigh HRT risk by several-fold.
The benefits that belong in the same conversation
- Vasomotor and quality-of-life symptoms: 70–90% improvement.
- Cardiovascular disease: HRT started under 60 or within 10 years of menopause reduces cardiovascular events by around 30% (the ‘window of opportunity’).
- Osteoporosis: reduces hip fracture risk by around 40% while in use.
- Type 2 diabetes: 30% reduction in incidence.
- Colorectal cancer: modest reduction with combined HRT.
- Cognitive function and dementia: emerging evidence of protection when started early.
- All-cause mortality: the WHI oestrogen-only arm showed a reduction in all-cause mortality in women starting under 60.
What raises risk independently of HRT
- Being overweight (BMI over 30) — the single largest modifiable risk factor after age.
- Alcohol — the risk begins from the first drink, not from ‘heavy’ drinking; each 10 g/day adds ~7–10% relative risk.
- Physical inactivity — regular exercise reduces risk by ~15–20%.
- Late age at first pregnancy or no pregnancies.
- Family history and BRCA gene mutations.
- Dense breasts (dense mammograms).
Personalising the decision
- Family history, breast density, BRCA status, previous breast disease and current lifestyle all matter.
- For most women without red flags, the benefits of well-prescribed HRT under age 60 outweigh a small personal risk.
- For women at higher baseline risk (dense breasts, family history), we often lean towards transdermal oestrogen + micronised progesterone or a Mirena, at the lowest effective dose.
- For women at very high risk (BRCA carriers, previous breast cancer), the conversation shifts — see the ‘HRT after breast cancer’ guide and always involve your oncology team.
Reducing what is modifiable
- Stay a healthy weight — the single biggest lever.
- Move daily; two strength sessions and 150 minutes of moderate cardio weekly.
- Keep alcohol modest (under 14 units/week, ideally under 5).
- Don’t smoke.
- Choose transdermal oestrogen and micronised progesterone (or Mirena) where clinically appropriate.
- Review your HRT regimen annually so you are on the lowest effective dose that fully controls symptoms.
Screening and surveillance
- Attend NHS breast screening every 3 years from age 50 to 71 — HRT users included.
- Continue monthly self-checks between screens.
- Report any new lump, skin change, nipple change, discharge or one-sided pain to your GP the same week, whether or not you take HRT.
- Some private clinics offer supplementary breast MRI or ultrasound for women with dense breasts — discuss with your clinician.
Common myths, answered plainly
- ‘HRT causes breast cancer’ — no. It slightly promotes existing cancers in some cases, and only some regimens do that.
- ‘I can’t take HRT because my mother had breast cancer’ — usually not true. Family history nuances the discussion; it rarely closes it.
- ‘I should stop HRT at 5 years’ — arbitrary. Decisions about continuation are individual and reviewed annually.
- ‘Body-identical HRT has no risk’ — very low risk is not the same as no risk; but the profile is markedly more favourable than older regimens.
Key takeaway
For most women under 60 without red flags, well-prescribed HRT — transdermal oestrogen with micronised progesterone or a Mirena — offers substantial benefits with a small, personal, dose- and duration-dependent breast cancer risk that is often smaller than lifestyle factors already in your life. This is a shared, informed decision, reviewed annually — not a formula.
How Dr Awal approaches this in clinic
Every consultation starts with your full story — symptoms, cycle, medical history, family history and what you've already tried. From there we look at whether hormonal treatment, non-hormonal options, lifestyle changes or a combination will give you the best result, and we tailor the plan to your age, risk factors and preferences.
- A detailed 60 minute first appointment — no rushed 10-minute slots.
- Evidence-based recommendations aligned with NICE NG23 and BMS guidance.
- Body-identical HRT considered first-line where appropriate.
- Shared-care letters sent to your NHS GP so treatment can continue affordably.
- Follow-up at 3 months to fine-tune your regimen and address side effects.
- Ongoing annual reviews so your plan evolves with you.
Common questions we hear about this
Do I need to be at a certain age to be seen?
No. We see women in early perimenopause (often late 30s and 40s), through post-menopause and beyond. Age alone doesn't decide whether treatment is right — symptoms, health history and goals do.
Will my GP continue the prescription?
In most cases yes. After your consultation we send a detailed shared-care letter with the diagnosis, treatment plan and rationale so your NHS GP can prescribe on the NHS. Not every practice accepts shared care — we'll discuss this in your appointment.
What if I've tried HRT before and it didn't suit me?
Very common — often the type, dose or route wasn't right rather than HRT itself. We review what you've tried, why it didn't work, and adjust accordingly. Many women who thought HRT wasn't for them do well on a different preparation.
How long will I need to stay on treatment?
There is no set upper time limit for HRT. Current BMS and NICE guidance supports continuing HRT for as long as the benefits outweigh the risks for you personally. We review this together every year so you stay in control of the decision.
Where do you see patients?
All consultations at Pause and Co Healthcare are conducted securely via video, allowing us to support patients anywhere in the UK. Prescriptions and shared care arrangements are managed in the same way, regardless of your location.
About the author
Dr Nadira Awal is a British Menopause Society Advanced Menopause Specialist with 15+ years' NHS and private experience. She holds the BMS Advanced Certificate in Menopause Care, sits on the BMS Programme Planning Group, and advises the UK Government Menopause Strategy Group. Read her full profile.
Sources & further reading
General information only — not a substitute for personalised medical advice. Always speak to your GP or a menopause specialist about your own situation.
Talk it through
Book a private consultation with Dr Awal
Get evidence-based, personalised advice on hrt and breast cancer risk — what the uk evidence says and any related concerns.
Related in HRT
Continue reading
A Comprehensive Guide to HRT
Types of HRT, oestrogen vs progesterone, benefits, side effects — and how to manage them.
Read guide
NHS vs Private HRT in the UK
How NHS and private HRT compare — costs, wait times, choice of preparations and how to transfer prescriptions.
Read guide
HRT Shortages in the UK
Why HRT supply issues happen, current UK availability and safe swaps if your prescription is unavailable.
Read guide